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Abstract
Background: Advanced melanoma is characterized by a pronounced resistance to therapy leading to a limited
patient survival of ~6 - 9 months. Here, we report on a novel bifunctional therapeutic fusion protein, designated
anti-MCSP:TRAIL, that is comprised of a melanoma-associated chondroitin sulfate proteoglycan (MCSP)-specific
antibody fragment (scFv) fused to soluble human TRAIL. MCSP is a well-established target for melanoma
immunotherapy and has recently been shown to provide important tumorigenic signals to melanoma cells. TRAIL
is a highly promising tumoricidal cytokine with no or minimal toxicity towards normal cells. Anti-MCSP:TRAIL was
designed to 1. selectively accrete at the cell surface of MCSP-positive melanoma cells and inhibit MCSP
tumorigenic signaling and 2. activate apoptotic TRAIL-signaling.
Results: Treatment of a panel of MCSP-positive melanoma cell lines with anti-MCSP:TRAIL induced TRAIL-mediated
apoptotic cell death within 16 h. Of note, treatment with anti-MCSP:sTRAIL was also characterized by a rapid
dephosphorylation of key proteins, such as FAK, implicated in MCSP-mediated malignant behavior. Importantly,
anti-MCSP:TRAIL treatment already inhibited anchorage-independent growth by 50% at low picomolar
concentrations, whereas > 100 fold higher concentrations of non-targeted TRAIL failed to reduce colony formation.
Daily i.v. treatment with a low dose of anti-MCSP:TRAIL (0.14 mg/kg) resulted in a significant growth retardation of
established A375 M xenografts. Anti-MCSP:TRAIL activity was further synergized by co-treatment with rimcazole, a
s-ligand currently in clinical trials for the treatment of various cancers.
Conclusions: Anti-MCSP:TRAIL has promising pre-clinical anti-melanoma activity that appears to result from
combined inhibition of tumorigenic MCSP-signaling and concordant activation of TRAIL-apoptotic signaling. Anti-
MCSP:TRAIL alone, or in combination with rimcazole, may be of potential value for the treatment of malignant
melanoma.
Background
Patients diagnosed with localized melanoma have a
10-year survival rate of up to 95%. In contrast, the life
expectancy of patients with metastasized melanoma is
limited to only 6 - 9 months [1]. The poor survival of
patients with advanced melanoma is largely attributable
to resistance towards current treatment modalities such
as chemo- and radiotherapy [2]. Therefore, the develop-
ment of novel therapeutic approaches that can trigger
melanoma-selective cell death appears warranted.
One target molecule of potential relevance for the
tumorigenicity of melanoma is the melanoma chondroitin
sulfate proteoglycan (MCSP), also known as high molecu-
lar weight melanoma associated antigen (HMW-MAA).
MCSP is highly expressed on the cell surface of both
benign dysplastic nevi and on over 85% of malignant
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correlates with an unfavorable prognosis [4]. Expression of
MCSP on normal tissue is mainly restricted to cells of the
melanocyte lineage, but has also been detected in basal
cells of the epidermis and within the hair follicle, in peri-
cytes, chondrocytes and smooth muscle cells [3]. Recent
studies have revealed that MCSP expression may provide
important tumorigenic signals to melanoma cells. MCSP
signaling stimulates growth, motility, and tissue invasion
by melanoma cells, e.g. by enhancing integrin function [5],
activation of Focal Adhesion Kinase (FAK) [6], mitogenic
ERK signaling [7] and matrix metalloproteinase 2 [8].
Furthermore, non-metastatic radial growth tumor cells
acquired anchorage-independent growth characteristics
upon ectopic expression of MCSP [6]. Of note, anti-MCSP
antibody treatment can partly inhibit MCSP-tumorigenic
signaling in vitro, as evidenced by a pronounced inhibition
of FAK [6].
Thus, MCSP appears to be important for melanoma
tumorigenicity and appears to be a promising target for
both naked monoclonal antibody (mAb) as well as
immunotoxin-based strategies [9,10]. Notably, anti-
MCSP mAbs proved to have beneficial effects on the
clinical course of the disease of melanoma patients
[3,11].
In recent years, we have demonstrated that scFv anti-
body fragment-targeted delivery of the immuno cytokine
TRAIL holds particular promise for tumor-selective
induction of apoptosis in various cancer types. TRAIL
(Tumor Necrosis Factor Related Apoptosis Inducing
Ligand) is a highly promising anti-cancer agent with
pronounced pro-apoptotic activity towards various
malignant cell types, including melanoma. Importantly,
TRAIL essentially lacks activity towards normal cells
[12]. Based on these characteristics, recombinant soluble
TRAIL (sTRAIL) preparations have recently entered
clinical trials, with promising preliminary reports on
anti-tumor activity and safety [13].
Antibody fragment-mediated targeting of TRAIL can
further selectively enhance the anti-tumor activity of
TRAIL towards various types of cancer, including carci-
nomas and Acute Myeloid Leukemia [12,14-20]. Briefly,
g e n e t i cf u s i o no fT R A I Lt oas c F va n t i b o d yf r a g m e n t
allows for the selective delivery of TRAIL to a pre-
selected tumor-associated antigen at the tumor cell sur-
face. The resulting high levels of tumor cell surface
bound TRAIL then efficiently activate apoptotic signal-
ing via the agonistic TRAIL-receptors TRAIL-R1 and
TRAIL-R2 in a mono- and/or bi/multicellular manner
[14-18,20]. Of note, non-targeted sTRAIL has no intrin-
sic tumor-selective binding activity and is less efficient
in cross-linking and activating TRAIL-R2 [21].
Here we preclinically evaluated the anti-melanoma
activity of MCSP-targeted delivery of TRAIL, using
fusion protein anti-MCSP:TRAIL. Anti-MCSP:TRAIL
was designed to selectively bind to MCSP at the cell
surface of melanoma cells and simultaneously inhibit
tumorigenic signaling by MCSP. Once bound to MCSP-
expressing melanoma cells, the anti-MCSP:TRAIL fusion
protein can activate apoptotic TRAIL-signaling. Since
TRAIL resistance has been reported for melanoma [22]
we further evaluated a combinatorial strategy in which
anti-MCSP:TRAIL treatment was combined with rimca-
zole. Rimcazole is a sigma receptor (sR) ligand currently
in clinical trials for various cancers that has shown
potent single-agent anti-tumor activity towards glioma
and breast cancer [23,24]. Sigma ligand-based therapy
may also be of value for the treatment of melanoma
since the two subtypes of s-Rs, s-R1 and s-R2 are
strongly overexpressed in this tumor [25,26].
MCSP targeting with anti-MCSP:TRAIL indeed
appeared to inhibit MCSP-signaling and activated
TRAIL-apoptotic signaling in melanoma cells in vitro
and in vivo. Furthermore, TRAIL-apoptotic signalling in
melanoma cells can be further increased by combinator-
ial treatment with rimcazole. The dual anti-melanoma
activity of anti-MCSP:TRAIL alone, or in combination
with rimcazole, may be of interest for treatment of
melanoma.
Results and Discussion
MCSP-restricted induction of apoptosis by
anti-MCSP:TRAIL
We and others have previously demonstrated that selec-
tive delivery of the cytokine TRAIL by genetic fusion to
an appropriate tumor-selecti v es c F va n t i b o d yf r a g m e n t
significantly enhances the anti-tumor activity of TRAIL
towards the corresponding type of cancer [14-20]. Here,
we adapted this targeted approach to malignant mela-
noma by exploiting an anti-MCSP scFv antibody frag-
ment that was derived from the well-established
monoclonal antibody (mAb) 9.2.27. The resultant fusion
protein, anti-MCSP:TRAIL, was equipped to selectively
accrete at the cell surface of MCSP-positive cells only
and subsequently trigger TRAIL-mediated apoptosis.
Indeed, treatment of MCSP-transfected M14 mela-
noma cells (M14.MCSP) with anti-MCSP:TRAIL
resulted in dose-dependent activation of apoptosis
within 16 h, whereas parental MCSP-negative M14 cells
were resistant to treatment with anti-MCSP:TRAIL
(Figure 1A). Similarly, treatment of a series of MCSP-
positive cell lines (A375M, A2058 and SK-MEL-28) with
anti-MCSP:TRAIL resulted in a marked induction of
apoptosis (Figure 1B). In a control experiment we
treated the same series of melanoma cells with fusion
protein anti-EpCAM:TRAIL, a fusion protein that is
essentially identical to anti-MCSP:TRAIL except that it
contains an anti-EpCAM scFv instead of an anti-MCSP
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Figure 1 MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL. A M14 and M14.MCSP cells were treated with increasing
concentrations of anti-MCSP:TRAIL for 16 h and apoptosis was assessed by Δψ. B MCSP-negative cell line M14 and MCSP-positive cell lines M14.
MCSP, SK-MEL-28, A2058 and A375M were treated with 500 ng/ml anti-MCSP:TRAIL for 16 h and apoptosis was assessed by Δψ. C A375M, A2058
and SK-MEL-28 cells were treated with equimolar concentrations of anti-MCSP:TRAIL, anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL
+anti-MCSP mAb for 16 h and apoptosis was assessed by Δψ. D A2058 cells were treated with 500 ng/mL anti-MCSP:TRAIL in the absence or
presence of parental MCSP-blocking mAb 9.2.27, TRAIL-neutralizing mAb 2E5 or pan-caspase inhibitor zVAD-fmk for 16 h and apoptosis was
assessed by Δψ. E A375M and A375M.FADD-DED cells were treated with anti-MCSP:TRAIL or rhTRAIL for 16 h and apoptosis was assessed by Δψ.
F A375M cells were incubated with anti-TRAIL-R1 (thin line) or anti-TRAIL-R2 (thick line) mAb and expression of TRAIL-R1 and TRAIL-R2 was
analyzed by flow cytometry. Shaded area indicates the fluorescence signal when cells were incubated with fluorescent-labeled secondary
antibody alone.
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Page 3 of 14scFv antibody fragment [14]. EpCAM is a well estab-
lished carcinoma-associated cell surface target antigen
that is not expressed on melanoma cells. Indeed, no
signs of apoptosis were observed when A375M, A2058
or SK-MEL-28 cells were treated with anti-EpCAM:
TRAIL (Figure 1C, Additional file 1, Figure S1A).
Treatment of MCSP-positive A375M, A2058 or
SK-MEL-28 cells with the parental anti-MCSP antibody
mAb 9.2.27 failed to induce any signs of apoptosis
(Figure 1C). Importantly, also co-treatment with MAb
9.2.27 and anti-EpCAM:TRAIL did not induce any sig-
nificant signs of apoptosis (Figure 1C). Thus, treatment
of MCSP-positive melanoma cells with fusion protein
anti-MCSP:TRAIL efficiently activates apoptosis that is
MCSP-restricted and that is superior to combined treat-
ment with TRAIL and the parental anti-MCSP mAb
9.2.27.
Induction of apoptosis by anti-MCSP:TRAIL was
abrogated when treatment was performed in the pre-
sence of the parental mAb 9.2.27 (Figure 1D). Thus,
anti-MCSP:TRAIL activity is strictly dependent on bind-
ing to cell surface-expressed MCSP on malignant cells.
Furthermore, addition of the TRAIL-neutralizing mAb
2E5 fully abrogated the apoptotic effect of anti-MCSP:
TRAIL (Figure 1D), indicating that induction of apopto-
sis is dependent on interaction of TRAIL with its ago-
nistic TRAIL-receptors. In addition, induction of
apoptosis was inhibited when treatment is performed in
the presence of pan-caspase-inhibitor zVAD-fmk (Figure
1D), further suggesting involvement of TRAIL-mediated
apoptotic signaling. Indeed, treatment of melanoma cells
with anti-MCSP:TRAIL was characterized by time-
dependent activation of initiator caspase-8 (Additional
file 1, Figure S1B) as well as effector caspases 3 and 7
(Additional file 1, Figure S1C).
To further confirm that TRAIL-signaling is involved,
the mutant cell line A375M.FADD-DED that ectopically
overexpresses a dominant negative mutant of the adap-
tor protein FADD, was produced. FADD is a pivotal
adaptor protein in TRAIL-receptor signaling. The
mutant FADD protein lacks the so-called DED domain,
which results in a general and strong resistance against
TRAIL-mediated apoptosis. Indeed, TRAIL-mediated
apoptotic signaling was fully halted in A375M.FADD-
DED cells, as is evidenced by the fact that these cells
were fully resistant to ubiquitously active recombinant
human TRAIL (rhTRAIL) (Figure 1E). Likewise, A375M.
FADD-DED cells were also fully resistant to treatment
with anti-MCSP:TRAIL (Figure 1E). Taken together,
these data clearly demonstrate that the pro-apoptotic
activity of anti-MCSP:TRAIL is TRAIL-mediated.
Previously, we and others have shown that upon bind-
ing to the respective target antigen, scFv:TRAIL fusion
proteins can efficiently activate TRAIL-R2, whereas
untargeted sTRAIL preparations have a markedly
reduced capacity to activate TRAIL-R2 signaling. Indeed
A375M cells, that solely express TRAIL-R2 at the cell
surface are sensitive to treatment with anti-MCSP:
TRAIL (Figure 1B, Additional file 1, Figure S1E), indi-
cating that anti-MCSP:TRAIL can potently activate
TRAIL-R2 signaling in MCSP-positive melanoma cells.
This feature may be of special relevance for melanoma
since TRAIL-R2 is the most prevalent agonistic TRAIL-
receptor expressed on melanoma cells [27].
Potent inhibition of anchorage-independent growth by
anti-MCSP:TRAIL
The MCSP antibody fragment used in this study was
derived from mAb 9.2.27. In earlier studies, mAb 9.2.27
partly inhibited MCSP-tumorigenic signaling in vitro,a s
evidenced by inhibition of FAK [9]. Since ectopic
expression of MCSP was also recently shown to induce
anchorage-independent growth capacity, anti-MCSP:
TRAIL was evaluated for its effect on anchorage-inde-
pendent growth of melanoma cells. In a soft agar assay,
treatment of the MCSP-positive cell lines A375M and
A2058 cells with anti-MCSP:TRAIL abrogated colony
outgrowth in a dose-dependent manner (Figure 2A). Of
note, anti-MCSP:TRAIL reduced colony formation by
50% already at very low concentrations (0.1 ng/ml and
1ng/ml for A375M and A2058 cells, respectively).
Induction of apoptosis by anti-MCSP:TRAIL at these
concentrations in adherent growth conditions was mar-
ginal (see Additional file 1, Figure S1E for dose-response
curves of apoptosis induction). In contrast, treatment
with similar concentrationso fa n t i - E p C A M : T R A I Lo r
with anti-MCSP mAb 9.2.27 only marginally reduced
colony formation (Figure 2B). Importantly, also combi-
natorial treatment with equimolar concentrations of
anti-EpCAM:TRAIL and mAb 9.2.27 failed to signifi-
cantly inhibit colony outgrowth of A375M cells at the
highest concentrations tested (Figure 2B). Furthermore,
rhTRAIL failed to significantly reduce colony outgrowth
(Figure 2C). Thus, anti-MCSP:TRAIL uniquely and effi-
ciently prevents colony outgrowth.
Treatment of A375M cells with anti-MCSP:TRAIL in
the presence of the TRAIL-neutralizing mAb 2E5 largely
blocked the effect of anti-MCSP:TRAIL on colony out-
growth (Figure 2D). Similarly, treatment of cells with
anti-MCSP:TRAIL in the presence of the parental anti-
MCSP mAb 9.2.27 inhibited anti-MCSP:TRAIL activity,
although the number of colonies still remained signifi-
cantly lower than medium control (Figure 2D). Of note,
co-incubation with pan-caspase inhibitor zVAD-fmk
abrogated the inhibitory effect of anti-MCSP:TRAIL on
colony outgrowth (Figure 2D), suggesting that apoptotic
signaling is required for the inhibitory effect of anti-
MCSP:TRAIL.
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Figure 2 Inhibition of anchorage-independent growth by anti-MCSP:TRAIL. A A375M and A2058 cells were treated with increasing
concentrations of anti-MCSP:TRAIL for 21 days and colony formation was assessed. B A375M cells were treated with increasing concentrations of
anti-MCSP:TRAIL, anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL+anti-MCSP mAb for 21 days and colony formation was assessed.
C A375M cells were treated with rhTRAIL, anti-EpCAM:TRAIL or anti-MCSP:TRAIL for 21 days and colony formation was assessed. D A375M cells
were treated with 100 ng/ml anti-MCSP:TRAIL in the absence or presence of TRAIL-neutralizing mAb 2E5, parental anti-MCSP mAb 9.2.27 or pan-
caspase inhibitor zVAD-fmk for 21 days and colony formation was assessed. E A375M and A375M.FADD-DED cells were treated with increasing
concentrations of anti-MCSP:TRAIL for 21 days and colony formation was assessed. F A375M.FADD-DED cells were treated with increasing
concentrations of anti-MCSP:TRAIL, anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL+anti-MCSP mAb for 21 days and colony formation
was assessed.
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signaling was required for the inhibitory effect of anti-
MCSP:TRAIL on colony outgrowth, TRAIL-resistant
A375M.FADD-DED cells were treated with anti-MCSP:
TRAIL. Importantly, colony formation of A375M.
FADD-DED cells was inhibited by anti-MCSP:TRAIL
treatment although ~50-100 fold higher concentrations
were required to obtain the same magnitude of inhibi-
tion as observed for parental A375M cells (Figure 2E).
Of note, treatment of A375M.FADD-DED cells with
anti-EpCAM:TRAIL did not inhibit colony formation
(Figure 2F), nor did combination treatment of anti-
EpCAM:TRAIL and mAb 9.2.27 (Figure 2F). In contrast,
mAb 9.2.27 alone did significantly inhibit colony out-
growth in this cell line, although to a lesser extent than
anti-MCSP:TRAIL (Figure 2F). Together, these experi-
mental data suggest that the simultaneous interaction of
anti-MCSP:TRAIL with MCSP and TRAIL-receptors
uniquely blocks anchorage-independent growth of mela-
noma cells at low concentrations.
Anti-MCSP:TRAIL dephosphorylates proteins involved in
cell proliferation and apoptosis resistance
The efficacy of anti-MCSP:TRAIL on inhibition of colony
formation by melanoma cells in 3D-culture suggests that
antibody fragment-dependent sensitization of cells to
concurrent TRAIL-signaling may contribute to its thera-
peutic effect. Previously, we generated proof of concept
data for such dual therapeutic signaling with scFv:TRAIL
fusion proteins, using an scFv:TRAIL fusion protein that
targeted the Epidermal Growth Factor Receptor [16,19].
Here, the EGFR-inhibitory antibody fragment blocked
mitogenic EGFR-signaling and synergized TRAIL
apoptotic signaling [16,19]. To assess whether the
MCSP-specific antibody fragment might contribute to
the anti-tumor activity of anti-MCSP:TRAIL, a focused
set of 48 cellular phosphoproteins was examined for the
level of phosphorylation after treatment with anti-MCSP:
TRAIL (Figure 3A B), anti-MCSP mAb 9.2.27 (Figure
3C) and rhTRAIL (Figure 3D). Interestingly, although
A375M cells were treated with anti-MCSP:TRAIL in
adherent growth conditions in view of experimental lim-
itations with 3D-cultures, significant dephosphorylation
of various proteins involved in cell survival and prolifera-
tion was detected after 1 h of treatment (Figure 3A, B
and Additional file 2, Table S1). This dephosphorylation
induced by anti-MCSP:TRAIL was detectable within
30 minutes and increased for up to 4 h after start of
treatment (Figure 3E). Treatment with mAb 9.2.27 and
rhTRAIL also triggered dephosphorylation of proteins at
1 h of treatment, but to a lesser extent and in a smaller
panel (Figure 3C and 3D, respectively).
First and foremost, the previously reported down-
stream target of MCSP, FAK, was dephosphorylated by
a factor 2 compared to medium control. The parental
anti-MCSP mAb 9.2.27 has been shown to prevent asso-
ciation of MCSP with integrins, thereby preventing acti-
vation of FAK [6]. Thus, although not determined here
for anti-MCSP:TRAIL, a similar inhibition of MCSP/
integrin interaction by the mAb 9.2.27-derived antibody
fragment may be responsible for the inhibitory effect of
anti-MCSP:TRAIL on FAK. Intriguingly, cross-linking of
MCSP by bead-coated mAb 9.2.27 has also been used to
achieve activation of MCSP-signaling [6]. The different
outcome of treatment with soluble vs. coated mAb sug-
gests that the extent of cross-linking of MCSP by the
antibody determines the activation or inhibition, respec-
tively, of downstream signaling. It will be interesting to
evaluate in future studies whether the three MCSP read-
ing heads in trimeric anti-MCSP:TRAIL are perhaps
better suited for inhibition of MCSP-signaling.
The activity of ERK1/2, another established down-
stream effector of MCSP signaling [6], was not affected
after 1 h of treatment with anti-MCSP:TRAIL. One pos-
sible reason for this finding is a perhaps delayed effect
of anti-MCSP:TRAIL on ERK1/2 signaling at later and
not examined time-points. In addition, it has been
shown that MCSP enhances FAK and Erk1/2 signaling
by distinct mechanisms [6]. It is therefore also conceiva-
ble that FAK is dephosphorylated while Erk1/2 is not a
target of inhibition by anti-MCSP:TRAIL.
In addition to the established MCSP-target FAK, a
panel of other proteins was dephosphorylated upon
anti-MCSP:TRAIL treatment, including the kinase Fyn,
and the Src kinases Src, Hck, Lyn and Yes. The relative
impact of these respective proteins on MCSP tumori-
genic signaling is currently being evaluated in extended
ongoing studies using e.g. constitutively active and/or
dominant negative mutants as well as small inhibitory
RNA-mediated silencing of the individual components.
Importantly, the above-mentioned experiments need to
be performed not only in 2D, but also in 3D-cultures, in
order to reliably determine the relative importance of
the here identified proteins for MCSP-dependent ancho-
rage-independent growth of melanoma cells.
Perhaps counter intuitively, the proto-oncogene Beta-
Catenin (b-Catenin) was also dephosphorylated by treat-
ment with anti-MCSP:TRAIL, as well as by treatment
with mAb 9.2.27 and rhTRAIL (Figure 3B,C and 3D,
respectively). Dephosphorylation of b-Catenin does not
inactivate b-Catenin but actually prevents proteasomal
degradation and increases cellular levels of b-Catenin. In
turn, this leads to activation of pro-oncogenic gene tran-
scription [28]. However, the exact role of b-Catenin-
induced gene transcription in melanoma is still a matter
of debate. Based on mouse models with activating muta-
tions in b-Catenin, an oncogenic role of b-Catenin in
melanoma was proposed [29]. On the other hand, others
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Figure 3 Anti-MCSP:TRAIL triggers dephosphorylation of cellular proteins. A375M cells were treated with anti-MCSP:TRAIL, anti-MCSP mAb
9.2.27, rhTRAIL or left untreated for 1 h. Whole cell lysates were analyzed for phosphorylation of 48 cellular kinases. A Phosphorylation of 28
kinases in untreated cells (left panel) or anti-MCSP:TRAIL-treated cells (right panel) are depicted. Images are representative of three independent
experiments. B, C, D Changes in the phosphorylation of 21 kinases after treatment with B anti-MCSP:TRAIL, C anti-MCSP mAb 9.2.27 or D
rhTRAIL are expressed as a percentage of the phosphorylation measured in untreated cells. E A375M cells were treated with anti-MCSP:TRAIL for
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Page 7 of 14have shown that b-Catenin induces a transcriptional
profile in melanoma cells that is reminiscent of normal
melanocyte differentiation [30]. This transcriptional pro-
file is moreover associated with increased patient survi-
val and is lost upon malignant progression [30].
Taken together, anti-MCSP:TRAIL dephosphorylates a
panel of established MCSP targets as well as newly
identified proteins (see Additional file 2, Table S1 for
overview). Thus, the kinase array data support a dual
anti-melanoma activity by anti-MCSP:TRAIL that partly
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Page 8 of 14relies on inhibition of tumorigenic signaling by the
anti-MCSP antibody fragment.
Anti-tumor activity of low dose anti-MCSP:TRAIL towards
A375M xenografts
To further characterize the anti-melanoma activity of
anti-MCSP:TRAIL, A375M cells were xenografted sub-
cutaneously in nude mice and allowed to form small
tumors (~ 50 mm
3). Subsequently, mice were treated
daily by intra-peritoneal injection with a low dose of
anti-MCSP:TRAIL (~ 0.14 mg/kg) or with saline. Of
note, anti-MCSP mAb 9.2.27 and therefore anti-MCSP:
TRAIL do not cross-react with mouse MCSP [3]. Com-
pared to sham-treated mice, tumor size of the anti-
MCSP:TRAIL-treated mice was strongly retarded in
time (Figure 4A), with a 50% reduction in tumor size at
the end of the experiment (Figure 4B). Of note, earlier
animal studies with A375M cells and non-targeted
rhTRAIL were performed at > 300 times higher concen-
trations (50 mg/kg) compared to the here employed
treatment regimen with anti-MCSP:TRAIL [31]. Thus,
in analogy to the low dose required for therapeutic
activity in colony formation assays, anti-MCSP:TRAIL
already has potent in vivo anti-melanoma activity at a
very low dose.
Anti-MCSP:TRAIL lacks apoptotic activity towards
normal cells
Earlier studies have shown that tumor targeted delivery
of TRAIL augments the tumor-specific activity of
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Page 9 of 14TRAIL, while not affecting the absence of toxicity on
normal human cell types. Indeed, although anti-MCSP:
TRAIL strongly bound to MCSP on normal human mel-
anocytes (Additional file 1, Figure S1D), no apoptosis
was induced in melanocytes even when treatment was
performed with 4 μg/ml anti-MCSP:TRAIL (Figure 4C).
Also extended treatment (up to 8 days) of melanocytes
with 4 μg/ml anti-MCSP:TRAIL did not yield significant
increases in apoptosis compared to medium control
(Figure 4D). Similarly, normal human MCSP-negative
hepatocytes were fully resistant to treatment with anti-
MCSP:TRAIL (Figure 4C). Hepatocytes have previously
been shown to be one of the most vulnerable normal
cell types to possible TRAIL-related toxicity [32]. Impor-
tantly, also in nude mice carrying A375M xenografts
treatment with anti-MCSP:TRAIL had no deleterious
effect on liver morphology, with morphology of liver
sections comparable to the morphology of liver sections
of Sham-treated mice (Figure 4E and 4F). The here
obtained data regarding the absence of activity of anti-
MCSP:TRAIL towards normal cell types are in line with
the large body of evidence in literature on the preclinical
safety profile of sTRAIL. Indeed, ongoing clinical trials
with rhTRAIL confirm the relative safety of TRAIL
treatment with no serious adverse effects and no dose-
limiting toxicity reported to date.
Synergistic induction of apoptosis by anti-MCSP:TRAIL
and s-ligands
Since resistance of melanoma cells towards sTRAIL has
previously been reported [22] a combinatorial strategy
was evaluated of anti-MCSP:TRAIL with rimcazole, a
s-ligand in clinical trials for various cancers. Sigma
receptors are expressed in the central nervous, immune,
endocrine, and reproductive systems, but also in periph-
eral organs like kidney, liver and gastrointestinal tract.
Although the precise function of these receptors
remains unknown, both s-R1 and s-R2 are strongly
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Figure 6 Schematic representation of the anti-melanoma activity of anti-MCSP:TRAIL. A Direct or indirect MCSP-mediated signaling
involves (integrin-dependent) FAK and Src phosphorylation and maintains phosphorylation of downstream transcription factors and apoptotic
modulators. MCSP thus contributes to pro-survival and metastatic signals. B Binding of anti-MCSP:TRAIL inhibits MCSP-mediated signaling and
concomitant activation of pro-metastatic/-survival signals and thereby sensitizes cells to apoptosis induction via binding of the TRAIL moiety to
TRAILR.
de Bruyn et al. Molecular Cancer 2010, 9:301
http://www.molecular-cancer.com/content/9/1/301
Page 10 of 14overexpressed in rapidly proliferating cells such as mela-
noma and may be exploited as possible targets for mela-
noma therapy [26]. Treatment of A375M cells with the
s-R1/s-R2 antagonist rimcazole synergistically enhanced
induction of apoptosis by anti-MCSP:TRAIL (Figure 5A
and 5B). Of note, treatment in the presence of the s-R1
agonist (+)pentazocine did not abrogate synergy, sug-
gesting that rimcazole synergizes with anti-MCSP:
TRAIL activity via s-R2 (Figure 5C). Rimcazole did not
upregulate TRAIL-R1 or TRAIL-R2 expression (data not
shown), but augmented the activation of initiator cas-
pase-8 and initiator caspase-9 upon anti-MCSP:TRAIL
treatment (Additional file 3, Figure S2A and B, respec-
tively). Moreover, inhibition of either initiator caspase
abrogated cytotoxic activity (Additional file 3, Figure
S2C). Thus, rimcazole appears to synergize the activity
of anti-MCSP:TRAIL by promoting caspase-8 activation.
Of note, anti-MCSP:TRAIL in combination with rimca-
zole lacked apoptotic activity towards hepatocytes
(Figure 5D), suggesting that this combination retains the
favorable toxicity profile associated with TRAIL and
rimcazole alone.
Conclusions
We provide evidence that anti-MCSP:TRAIL, a TRAIL
fusion protein targeted to melanoma-expressed MCSP,
inhibits MCSP tumorigenic signaling and simultaneously
induces TRAIL apoptotic signaling. Consequently, fusion
protein anti-MCSP:TRAIL potently inhibits outgrowth of
melanoma cells both in vitro and in vivo and this effect
can be further enhanced with the cytotoxic agent rimca-
zole. Based on the above, we postulate the following work-
ing model for anti-MCSP:TRAIL (see also Figure 6B);
anti-MCSP:TRAIL binds to MCSP and inhibits MCSP-
signaling, which includes inhibition of src-kinases and
FAK, the STAT transcription factors, and various anti-
apoptotic modulators such as p53, TOR, JNK. Concur-
rently, interaction of the sTRAIL domain with its agonistic
receptors TRAIL-R1 and TRAIL-R2 triggers potent induc-
tion of apoptosis. Notably, TRAIL/TRAIL-R interaction
also triggers dephosphorylation of the STAT family, which
may contribute to sensitization of cells to apoptosis
[33,34]. Thus, melanoma cells are eliminated on the one
hand by MCSP-mediated sensitization of melanoma cells
to apoptosis and on the other hand by the concurrent acti-
vation of TRAIL-apoptotic signaling. Taken together, anti-
MCSP:TRAIL is a novel immunotherapeutic agent that,
either alone or in combination with rimcazole, may be of
potential value for treatment of advanced melanoma.
Methods
Reagents
MAb 9.2.27 is a murine IgG2a with high binding affinity
for human MCSP [10]. TRAIL-neutralizing mAb 2E5
was purchased from Alexis (10P’s, Breda, The Nether-
lands). Caspase inhibitors zVAD-fmk and zLEHD-fmk
were from Calbiochem (VWR International B.V.,
Amsterdam, The Netherlands) and dissolved at 10 mM
in DMSO. Rimcazole (BW 239U) and (+)pentazocine
were from Sigma Aldrich (Sigma-Aldrich Chemie B.V.
Zwijndrecht, Netherlands). Stock solutions of rimcazole
(3.9 mM in ethanol) and pentazocine (10 mM in 0.1 N
hydrochloric acid) were freshly prepared for each
experiment.
Cell lines
MCSP-positive/EpCAM-negative melanoma cell lines
A375M, A2058 and SK-MEL-28 were obtained from
and characterized (STR profiling, karyotyping, isoen-
zyme analysis) by the American Tissue Culture Collec-
tion (ATCC). The MCSP-negative melanoma cell line
M14 and transfectant cell line M14.MCSP were pro-
v i d e db yP r o f .D r .G . H .F e y .E x p r e s s i o no fM C S Pw a s
determined by flow cytometry using anti-MCSP mAb
9.2.27 and a FITC-conjugated goat-anti-mouse mAb.
A375M.FADD-DED cells were generated by transfection
of parental A375M cells using Fugene (Roche BV,
Woerden, The Netherlands). All cell lines were cultured
at 37°C, in a humidified 5% CO2 atmosphere. A375M,
A2058, SK-MEL-28 and M14 cells were cultured in
RPMI 1640 medium (Cambrex Bio Science, Verviers,
France) supplemented with 10% fetal calf serum. M14.
MCSP cells were cultured in RPMI 1640 medium sup-
plemented with 10% fetal calf serum and 400 μg/ml
Geneticin. A375M.FADD-DED cells were cultured in
RPMI 1640 medium supplemented with 10% fetal calf
serum and 500 μg/ml Geneticin.
Primary human hepatocytes (PHH) and melanocytes
Cryopreserved human hepatocytes and melanocytes
(Tebu-bio bv, Heerhugowaard, The Netherlands) were
isolated according to standard protocol using hepatocyte
isolation kit and melanocyte isolation kit, respectively
(tebu-bio bv, Heerhugowaard, The Netherlands). For
experiments, hepatocytes and melanocytes were seeded
in a 48-well plate at a density of 0.5 × 10
6 cells/ml.
Construction of fusion protein anti-MCSP:TRAIL
A scFv antibody fragment in the VH-VL format was
derived from mAb 9.2.27 using standard antibody-phage
display technology [10]. Fusion protein anti-MCSP:
TRAIL was constructed by cloning the cDNA of anti-
body fragment MCSP in frame with soluble TRAIL into
in-house constructed vector pEE14 using unique SfiI
and NotI restriction enzyme sites, yielding plasmid
pEE14-anti-MCSP:TRAIL. Fusion protein anti-MCSP:
TRAIL was produced in CHO-K1 cells using previously
described methods [14,16]. Culture medium containing
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(10 000 g, 10 min), filter sterilized, and stored at -80°C
until further use. Fusion protein anti-MCSP:TRAIL
was purified via the N-terminal Hemagglutinin (HA)-
tag using anti-HA affinity chromatography. Fusion
protein scFvC54:sTRAIL [14], for reasons of clarity
hereafter renamed into anti-EpCAM:TRAIL, is a fusion
protein that is essentially identical to anti-MSCP:
T R A I Le x c e p tt h a ti tc o n t a i n sa na n t i - E p C A Ms c F v
instead of an anti-MSCP scFv.
Assessment of apoptosis
MCSP-restricted induction of apoptosis by anti-MCSP:
TRAIL was assessed on a panel of melanoma cell lines.
Briefly, melanoma cells were pre-cultured in a 48-well
plate at a concentration of 3 × 10
4 cells/well. Subse-
quently, cells were treated as indicated and apoptosis
was assessed by: Loss of mitochondrial membrane
potential (Δψ); Δψ was analyzed by DiOC6 staining
(Eugene, The Netherlands) as previously described [16].
After 16 h treatment, cells were harvested and incubated
f o r2 0m i nw i t hD i O C 6( 0 . 1μM) at 37°C, harvested
(1000 g, 5 min.), resuspended in PBS, and assessed for
staining by flow cytometry. Caspase-8, caspase-9 and
caspase-3/-7 activity; caspase activity was assessed
using the Caspase-Glo 8, 9 and 3/7 Assay according to
manufacturer’s instructions (Promega Benelux BV,
Leiden, The Netherlands). The assay is based on the
cleavage of non-luminescent substrates by activated cas-
pases into a luminescent product. Luminescence was
quantified using a Victor3 multi-label plate reader (Per-
kin Elmer, Groningen, The Netherlands)
Soft agar colony forming assay
Soft agar colony forming assays were performed in
24-well plates pre-coated with 0.5 ml solidified 0.4% agar-
ose in RPMI 1640 medium. Cells were resuspended at a
density of 10 × 10
3 cells/well in 0.6% agarose in RPMI
1640 medium supplemented with 20% fetal calf serum
and layered on the solidified 0.4% agarose in a 24-well
plate. Tumor cell containing agarose was allowed to soli-
dify for 10 minutes at 4°C before addition of 1 ml of
RPMI 1640 medium supplemented with 20% fetal calf
serum. Cells were treated as indicated and subsequently
cultured at 37°C, in a humidified 5% CO2 atmosphere.
Colony formation was assessed 21 days after start of
treatment. Assays were performed in quadruplicate.
Number of colonies was quantified and percentage of
colony growth was calculated with the formula: Percen-
tage of colony growth = (number of colonies in experi-
mental condition)/(number of colonies in medium
control) × 100%. For A375M cells, the number of colo-
nies in untreated samples ranged from 30 ± 5 to 262 ±
35 between individual experiments.
Proteome Profiler array
The effect of MCSP targeting on protein tyrosine kinase
activity was assessed by the Human Phospho-Kinase
Array Kit (R&D Systems) according to the manufac-
turer’s recommendations. Briefly, per condition 1 × 10
7
cells were treated for 0, 30, 60, or 240 min. at 37°C as
indicated. Lysate (500 μg/condition) was added to the
NC-membranes containing spotted Phospho-Kinase
(PK) antibodies. Subsequently, secondary Biotin-
conjugated anti-Kinase antibodies and Horseradish Per-
oxidase-conjugated Streptavidin were added to detect the
presence of phosphorylated kinases. Between incubation
steps, membranes were rigorously washed. Blots were
developed by standard chemoluminescence (Roche).
Luminescent signals were quantified using the IVIS Spec-
trum bioluminescent imager (Caliper Biosciences) as
photons/sec/sr/cm2. After background luminescence
subtraction, the relative kinase activity in treated condi-
tions was calculated by the formula: (PK activity experi-
mental condition/PK activity medium control) × 100%.
A375M xenograft mouse model
Experiments involving animals were performed in accor-
dance with the experimental protocol approved by the
Committee for Research and Animal Ethics of the
UMCG. Six week old healthy male athymic mice (n = 8)
were purchased from Harlan (Harlan Netherlands B.V.,
Horst, The Netherlands). Mice were housed in IVC
cages and fed ad libitum. Subsequently, mice were sub-
cutaneously inoculated with 2 × 10
6 A375M cells sus-
pended in 100 μl matrigel. Tumor growth was
monitored daily by electronic caliper measurements.
After reaching tumor size of ~ 50 ± 6 mm
3,m i c ew e r e
randomly assigned into two groups with a sample size
of 4. Mice received daily i.v. saline injections or
anti-MCSP:TRAIL injections (0.14 mg/kg). After two
weeks of treatment, mice were sacrificed by cervical
dislocation. Tumor size was calculated by the formula:
V = 0,5234 × H × L × W [mm3]. Tumor size was
expressed as the percentage of maximum tumor size in
Sham-treated mice.
Liver histopathology
Formalin-fixed liver samples were embedded in paraffin,
sectioned into 5-μm thickness and stained with hema-
toxylin-eosin and microscopically inspected for hepatic
tissue damage and inflammation.
Combination treatment with anti-MCSP:TRAIL
and s-ligands
Cells were plated at 3.0 × 10
4 cells/well in a 48-well
plate and allowed to adhere overnight. Cells were
concurrently treated for 24 h with anti-MCSP:TRAIL
with or without rimcazole (15 μM), and (+)pentazocine
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Page 12 of 14(200 nM). Synergy was assessed by calculating the coop-
erativity index (CI) in which the sum of apoptosis induced
by single-agent treatment is divided by apoptosis induced
by combination treatment. When CI was less than 1, treat-
ment was considered synergistic; when CI equaled 1, treat-
ment was considered additive; when CI was greater than 1,
treatment was considered antagonistic.
Statistical analysis
Data reported are mean values ± standard error of the
mean of at least three independent experiments. Statisti-
cal analysis was performed by one-way ANOVA fol-
lowed by Tukey-Kramer post test or by two-sided
unpaired Student’s t-test. p < 0.05 was defined as a sta-
tistically significant difference.
Additional material
Additional file 1: Figure S1. A A2058 cells were treated with increasing
concentrations of anti-MCSP:TRAIL or anti-EpCAM:TRAIL for 16 h and
apoptosis was assessed by Δψ. B A375M cells were treated with 500 ng/
mL anti-MCSP:TRAIL for the time-points indicated and caspase-8
activation was assessed. C A2058 cells were treated with 500 ng/mL anti-
MCSP:TRAIL in the absence or presence of parental MCSP-blocking mAb
9.2.27 or TRAIL-neutralizing mAb 2E5 and caspase-3/-7 activation was
assessed. D MCSP-restricted binding of anti-MCSP:TRAIL to melanocytes
was assessed. Specific binding was demonstrated by pre-incubating
melanocytes with mAb 9.2.27 followed by incubation with anti-MCSP:
TRAIL. Binding of anti-MCSP:TRAIL was assessed by flow cytometry using
a PE-conjugated anti-TRAIL mAb. E A2058 and A375M cells were treated
with increasing concentrations of anti-MCSP:TRAIL for 16 h and apoptosis
was assessed by Δψ.
Additional file 2: Table S1. Table containing the various kinases down
regulated by anti-MCSP:TRAIL, their role in oncology and the percentage
of inhibition after 1 h treatment with anti-MCSP:TRAIL.
Additional file 3: Figure S2. Activity of A Caspase-8, B Caspase-9 was
assessed in A375M cells after incubation with anti-MCSP:TRAIL in the
presence or absence of rimcazole (15 μM) for 1, 2, 3, 4, 5, 6 or 16 h C
A375M cells were treated for 16 h with 100 ng/mL of anti-MCSP:TRAIL
and/or rimcazole (15 μM) in the presence or absence of zVAD-FMK (20
μM) or zLEHD-FMK and apoptosis was assessed by Δψ.
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